Brazil Approves First Generic Version Of Sovaldi
Brazil’s first generic version of Sovaldi for hepatitis C is approved.
You may also be interested in...
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.
Mercosur bloc has been conducting joint negotiations on HCV drugs; cancer treatments may be next on the agenda.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.